Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism

NCT03029429 is registered in ClinicalTrials.gov with Vanderbilt University Medical Center as lead sponsor.

NCT NCT03029429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03029429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism
Lead sponsor
Vanderbilt University Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 1, 2018
Completion date
December 1, 2026
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

albright hereditary osteodystrophy, pseudohypoparathyroidism